EUVIMEDSkopri EUVIMED
Kohortenstudie

Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.

Aakash Desai iD, Priya Sehgal, Himsikhar Khataniar, James D Lewis, Francis A Farraye, Gary R Lichtenstein, Gursimran S Kochhar

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18513 ↗

At a glance

Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Aakash Desai and 6 co-authors. Institution: Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Major MEDLINE topics: Colitis, Ulcerative, Obesity, Gastrointestinal Agents. Cited 12 times so far (Crossref); 16 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Obesity has been linked to a more severe phenotype in patients with ulcerative colitis (UC).

Aim

To evaluate the impact of obesity on outcomes of advanced therapies in UC.

Methods

We conducted a retrospective cohort study utilising the TriNetX database comparing the composite score of corticosteroid use, change in advanced therapy or colectomy within two years between two cohorts of patients with UC—those with obesity (BMI ≥ 30 kg/m 2 ) and those without (BMI 18.5–24.9). The risk assessment was stratified to specific advanced therapies, including tumour necrosis factor α inhibitors (TNFi), vedolizumab, ustekinumab and Janus kinase inhibitors (JAKi). We performed 1:1 propensity score matching (PSM) for demographics, co‐morbid conditions, laboratory values and IBD medications including corticosteroids.

Results

There were 3904, 2025, 1150 and 477 patients on TNFi, vedolizumab, ustekinumab and JAKi, respectively, in the UC obesity cohort. After PSM, the UC obesity cohort was at an increased risk of the composite outcome of corticosteroid use, change in therapy and colectomy compared to the UC control cohort in patients on TNFi (aHR 1.37, 95% CI 1.29–1.49), vedolizumab (aHR 1.29, 95% CI 1.16–1.43), ustekinumab (aHR 1.1.26, 95% CI 1.10–1.44) and JAKi (aHR 1.38, 95% CI 1.13–1.69). Sub‐group analysis based on the specific TNFi also showed an increased risk of composite outcome for infliximab (aHR 1.36, 95% CI 1.22–1.52) and adalimumab (aHR 1.26, 95% CI 1.11–1.42) within 2 years.

Conclusions

Obesity is associated with lower efficacy of several advanced therapies in patients with UC.

Subjects

MeSH terms (MEDLINE)

Colitis, UlcerativeObesityGastrointestinal AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultPropensity ScoreUnited StatesTreatment OutcomeAntibodies, Monoclonal, HumanizedUstekinumabCohort StudiesColectomyJanus Kinase Inhibitors

Author keywords

advanced therapiesobesityulcerative colitis

Substances

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsUstekinumabJanus Kinase Inhibitors

Authors and institutions

  • Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
  • Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
  • Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Gastroenterology and Hepatology, Inflammatory Bowel Disease Centre, Mayo Clinic, Jacksonville, Florida, USA.

ORCID profiles: Aakash Desai

Cite

APA

Desai, A., Sehgal, P., Khataniar, H., Lewis, J. D., Farraye, F. A., Lichtenstein, G. R., & Kochhar, G. S. (2025). Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18513

Vancouver

Desai A, Sehgal P, Khataniar H, Lewis JD, Farraye FA, Lichtenstein GR, et al. Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18513

BibTeX
@article{Desai2025,
  author = {Desai, Aakash and Sehgal, Priya and Khataniar, Himsikhar and Lewis, James D and Farraye, Francis A and Lichtenstein, Gary R and Kochhar, Gursimran S},
  title = {Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18513}
}
Start for free →